Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | PAM | P19021 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528920 | 0.85 | MEN1 (0.49) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL6637645 | 0.83 | MEN1 (0.47) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL2229690 | 0.83 | MEN1 (0.66) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL11683148 | 0.81 | MEN1 (0.46) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL10661140 | 0.81 | LMNA (0.56) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL12500129 | 0.81 | LMNA (0.56) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL17311135 | 0.80 | AKR1C1 (0.46) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL368334 | 0.80 | CYP3A4 (0.51) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL11685413 | 0.79 | MEN1 (0.44) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 | |
| SCHEMBL1373611 | 0.79 | ALDH1A1 (0.50) | MEN1KMT2AAKR1C3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382601-A1 | EMULSION FORMULATION HAVING HIGH FORMULATION STABILITY AND MANUFACTURING METHOD THEREOF | AMOREPACIFIC CORPORATION (KR) | 2024-11-21 | — | — | US | claimed |
| US-10792238-B2 | Cosmetic composition having high dosage form stability | AMOREPACIFIC CORPORATION (KR) | 2020-10-06 | — | — | US | claimed |
| US-20190192412-A1 | COSMETIC COMPOSITION HAVING HIGH DOSAGE FORM STABILITY | AMOREPACIFIC CORPORATION (KR) | 2019-06-27 | — | — | US | claimed |
| US-10238624-B2 | Composition for activating longevity genes, containing kojic acid derivative as active ingredient | AMOREPACIFIC CORPORATION (KR) | 2019-03-26 | — | — | US | claimed |
| US-20180177702-A1 | COSMETIC COMPOSITION HAVING HIGH DOSAGE FORM STABILITY | AMOREPACIFIC CORPORATION (KR) | 2018-06-28 | — | — | US | claimed |
| US-20180078522-A1 | COMPOSITION FOR ACTIVATING LONGEVITY GENES, CONTAINING KOJIC ACID DERIVATIVE AS ACTIVE INGREDIENT | AMOREPACIFIC CORPORATION (KR) | 2018-03-22 | — | — | US | claimed |
| WO-2017003092-A1 | COSMETIC COMPOSITION HAVING HIGH DOSAGE FORM STABILITY | (주)아모레퍼시픽 | 2017-01-05 | — | — | WO | claimed |
| US-20120171156-A1 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LTD. (GB) | 2012-07-05 | — | — | US | claimed |
| EP-2442873-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | Hds Limited (GB) | 2012-04-25 | — | — | EP | claimed |
| WO-2010146142-A9 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2011-06-16 | — | — | WO | claimed |
| WO-2010146142-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2010-12-23 | — | — | WO | claimed |
| WO-2026104886-A1 | METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY | 유엔케이코리아 주식회사 | 2026-05-21 | — | — | WO | disclosed |
| EP-4656176-A1 | METHOD FOR ENCAPSULATING ACTIVE INGREDIENT AND IMPROVING STABILITY USING MICELLE | Amorepacific Corporation (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-12350352-B2 | Composition for surface modification | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-20240382601-A1 | EMULSION FORMULATION HAVING HIGH FORMULATION STABILITY AND MANUFACTURING METHOD THEREOF | AMOREPACIFIC CORPORATION (KR) | 2024-11-21 | — | — | US | disclosed |
| WO-2010056232-A1 | COMPOSITION WITH A COLOR MARKER | COLGATE PALMOLIVE COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056233-A1 | COMPOSITION WITH A COLOR TO INDICATE COVERAGE | COLGATE-PALMOLIVE COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008134712-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008070368-A2 | METHODS AND COMPOSITIONS FOR SKIN CARE | LIVING PROOF, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | MMP1, MMP9, MMP17 | MEN1 1603/4885KMT2A 2537/4885AKR1C3 4746/4885 |
| US-20180078522-A1 | COMPOSITION FOR ACTIVATING LONGEVITY GENES, CONTAINING KOJIC ACID DERIVATIVE AS ACTIVE INGREDIENT | ERCC1, ERCC4, ERCC2 | MEN1 2638/4885KMT2A 964/4885AKR1C3 1879/4885 |
| US-20180177702-A1 | COSMETIC COMPOSITION HAVING HIGH DOSAGE FORM STABILITY | CUTA, UGCG, MAN2A1 | MEN1 1919/4885KMT2A 449/4885AKR1C3 721/4885 |
| US-20190192412-A1 | COSMETIC COMPOSITION HAVING HIGH DOSAGE FORM STABILITY | CUTA, UGCG, MAN2A1 | MEN1 1919/4885KMT2A 449/4885AKR1C3 721/4885 |
| US-12350352-B2 | Composition for surface modification | CUTA, PTMS, DNMT1 | MEN1 3736/4885KMT2A 627/4885AKR1C3 2310/4885 |
| US-10792238-B2 | Cosmetic composition having high dosage form stability | CUTA, UGCG, MAN2A1 | MEN1 1919/4885KMT2A 449/4885AKR1C3 721/4885 |
| US-10238624-B2 | Composition for activating longevity genes, containing kojic acid derivative as active ingredient | ERCC1, ERCC4, ERCC2 | MEN1 2638/4885KMT2A 964/4885AKR1C3 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.